Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility

Journal of Clinical Microbiology

Volumn 48, Issue 12, 2010, Pages 4417-4425

  Endimiani, Andrea ^a,b   Perez, Federico ^a,b   Bajaksouzian, Saralee ^a   Windau, Anne R ^a   Good, Caryn E ^a   Choudhary, Yuvraj ^b   Hujer, Andrea M ^a,b   Bethel, Christopher R ^b   Bonomo, Robert A ^a,b   Jacobs, Michael R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BROTH DILUTION; DISK DIFFUSION; EPSILOMETER TEST; KLEBSIELLA PNEUMONIAE; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; MODIFIED HODGE TEST; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

KLEBSIELLA PNEUMONIAE;

EID: 78650069938     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02458-09     Document Type: Article

References (43)

1. Anderson, K. F., D. R. Lonsway, J. K. Rasheed, J. Biddle, B. Jensen, L. K. McDougal, R. B. Carey, A. Thompson, S. Stocker, B. Limbago, and J. B. Patel. 2007. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J. Clin. Microbiol. 45:2723-2725.
2. Bratu, S., M. Mooty, S. Nichani, D. Landman, C. Gullans, B. Pettinato, U. Karumudi, P. Tolaney, and J. Quale. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49:3018-3020.
3. Carrer, A., L. Poirel, H. Eraksoy, A. A. Cagatay, S. Badur, and P. Nordmann. 2008. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob. Agents Chemother. 52:2950-2954.
4. Carvalhaes, C. G., R. C. Picao, A. G. Nicoletti, D. E. Xavier, and A. C. Gales. 2010. Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false-positive results. J. Antimicrob. Chemother. 65:249-251.
5. CLSI. 2009. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
6. CLSI. 2010. Performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
7. CLSI. 2010. Performance standards for antimicrobial susceptibility testing; update. CLSI document M100-S20 June 2010 update. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Deshpande, L. M., R. N. Jones, T. R. Fritsche, and H. S. Sader. 2006. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb. Drug Resist. 12:223-230.
9. Deshpande, L. M., P. R. Rhomberg, H. S. Sader, and R. N. Jones. 2006. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005). Diagn. Microbiol. Infect. Dis. 56:367-372.
10. Doi, Y., B. A. Potoski, J. M. Adams-Haduch, H. E. Sidjabat, A. W. Pasculle, and D. L. Paterson. 2008. Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound. J. Clin. Microbiol. 46:4083-4086.
11. Doumith, M., M. J. Ellington, D. M. Livermore, and N. Woodford. 2009. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J. Antimicrob. Chemother. 63:659-667.
12. KPC in the United States. Antimicrob. Agents Chemother. 52:2680-2682.
13. Endimiani, A., Y. Choudhary, and R. A. Bonomo. 2009. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob. Agents Chemother. 53:3599-3601.
14. Endimiani, A., J. M. Depasquale, S. Forero, F. Perez, A. M. Hujer, D. Roberts-Pollack, P. D. Fiorella, N. Pickens, B. Kitchel, A. E. Casiano-Colon, F. C. Tenover, and R. A. Bonomo. 2009. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J. Antimicrob. Chemother. 64:1102-1110.
15. Endimiani, A., A. M. Hujer, F. Perez, C. R. Bethel, K. M. Hujer, J. Kroeger, M. Oethinger, D. L. Paterson, M. D. Adams, M. R. Jacobs, D. J. Diekema, G. S. Hall, S. G. Jenkins, L. B. Rice, F. C. Tenover, and R. A. Bonomo. 2009. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern U.S.A. J. Antimicrob. Chemother. 63:427-437.
16. Endimiani, A., K. M. Hujer, A. M. Hujer, E. S. Armstrong, Y. Choudhary, J. B. Aggen, and R. A. Bonomo. 2009. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53:4504-4507.
17. Frasca, D., S. Marchand, F. Petitpas, C. Dahyot-Fizelier, W. Couet, and O. Mimoz. 2010. Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients. Antimicrob. Agents Chemother. 54:924-926.
18. Frei, C. R., N. P. Wiederhold, and D. S. Burgess. 2008. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic- pharmacodynamic models with Monte Carlo simulation. J. Antimicrob. Chemother. 61:621-628.
19. Hoban, D. J., S. K. Bouchillon, S. P. Hawser, and R. E. Badal. 2010. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007. Diagn. Microbiol. Infect. Dis. 66:78-86.
20. Jacoby, G. A., D. M. Mills, and N. Chow. 2004. Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48:3203-3206.
21. Jaruratanasirikul, S., and T. Sudsai. 2009. Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. J. Antimicrob. Chemother. 63:560-563.
22. Jones, R. N., H. S. Sader, and T. R. Fritsche. 2005. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52:71-74.
23. Keam, S. J. 2008. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 68:2021-2057.
24. Landman, D., S. Bratu, S. Kochar, M. Panwar, M. Trehan, M. Doymaz, and J. Quale. 2007. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. J. Antimicrob. Chemother. 60:78-82.
25. Leavitt, A., I. Chmelnitsky, R. Colodner, I. Ofek, Y. Carmeli, and S. Navon-Venezia. 2009. Ertapenem resistance among extended-spectrum-beta- lactamase-producing Klebsiella pneumoniae isolates. J. Clin. Microbiol. 47:969-974.
26. Lee, K., Y. Chong, H. B. Shin, Y. A. Kim, D. Yong, and J. H. Yum. 2001. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase- producing strains of Pseudomonas and Acinetobacter species. Clin. Microbiol. Infect. 7:88-91.
27. Martinez-Martinez, L. 2008. Extended-spectrum beta-lactamases and the permeability barrier. Clin. Microbiol. Infect. 14(Suppl. 1):82-89.
28. McGettigan, S. E., K. Andreacchio, and P. H. Edelstein. 2009. Specificity of ertapenem susceptibility screening for detection of Klebsiella pneumoniae carbapenemases. J. Clin. Microbiol. 47:785-786.
29. Moczygemba, L. R., C. R. Frei, and D. S. Burgess. 2004. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin. Ther. 26:1800-1807.
30. Nakamura, T., C. Shimizu, M. Kasahara, K. Okuda, C. Nakata, H. Fujimoto, H. Okura, M. Komatsu, K. Shimakawa, N. Sueyoshi, T. Ura, K. Satoh, M. Toyokawa, Y. Wada, T. Orita, T. Kofuku, K. Yamasaki, M. Sakamoto, H. Nishio, S. Kinoshita, and H. Takahashi. 2009. Monte Carlo simulation for evaluation of the efficacy of carbapenems and new quinolones against ESBL-producing Escherichia coli. J. Infect. Chemother. 15:13-17.
31. Nicolau, D. P. 2008. Carbapenems: a potent class of antibiotics. Expert Opin. Pharmacother. 9:23-37.
32. Nicolau, D. P. 2008. Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit. Care 12(Suppl. 4):S2.
33. Nordmann, P., G. Cuzon, and T. Naas. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
34. Pasteran, F., T. Mendez, L. Guerriero, M. Rapoport, and A. Corso. 2009. Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. J. Clin. Microbiol. 47:1631-1639.
35. Paterson, D. L., K. M. Hujer, A. M. Hujer, B. Yeiser, M. D. Bonomo, L. B. Rice, and R. A. Bonomo. 2003. Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. Antimicrob. Agents Chemother. 47:3554-3560.
36. Paterson, D. L., L. B. Rice, and R. A. Bonomo. 2001. Rapid method of extraction and analysis of extended-spectrum beta-lactamases from clinical strains of Klebsiella pneumoniae. Clin. Microbiol. Infect. 7:709-711.
37. Perez, F., A. Endimiani, A. J. Ray, B. K. Decker, C. J. Wallace, K. M. Hujer, D. J. Ecker, M. D. Adams, P. Toltzis, M. J. Dul, A. Windau, S. Bajaksouzian, M. R. Jacobs, R. A. Salata, and R. A. Bonomo. 2010. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J. Antimicrob. Chemother. 65:1807-1818.
38. Perrott, J., V. H. Mabasa, and M. H. Ensom. 2010. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann. Pharmacother. 44:557-564.
39. Quale, J. 2008. Global spread of carbapenemase-producing Klebsiella pneumoniae. Microbe 3:516-520.
40. Queenan, A. M., and K. Bush. 2007. Carbapenemases: the versatile betalactamases. Clin. Microbiol. Rev. 20:440-458.
41. Robledo, I. E., E. E. Aquino, M. I. Sante, J. L. Santana, D. M. Otero, C. F. Leon, and G. J. Vazquez. 2009. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob. Agents Chemother. 54:1354-1357.
42. Tsakris, A., I. Kristo, A. Poulou, K. Themeli-Digalaki, A. Ikonomidis, D. Petropoulou, S. Pournaras, and D. Sofianou. 2009. Evaluation of boronic acid disk tests for differentiating KPC-possessing Klebsiella pneumoniae isolates in the clinical laboratory. J. Clin. Microbiol. 47:362-367.
43. Weisenberg, S. A., D. J. Morgan, R. Espinal-Witter, and D. H. Larone. 2009. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn. Microbiol. Infect. Dis. 64:233-235.